

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/171,740	04/20/1999	FRANCIS XAVIER IGNATIOUS	10391/003001	8400
75	590 02/12/2004		EXAM	INER
brian r. morril		BENNETT, RACHEL M		
biomeasure inc	•	ART UNIT	PAPER NUMBER	
27 maple street milford, MA			1615	
			D. TD. 44 V. ED. 00/10/004	

DATE MAILED: 02/12/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/171,740	IGNATIOUS ET AL.			
Office Action Summary	Examiner	Art Unit			
	Rachel M. Bennett	1615			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REP THE MAILING DATE OF THIS COMMUNICATION  - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a re - If NO period for reply is specified above, the maximum statutory perio - Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).	.  1.136(a). In no event, however, may a reply be timely within the statutory minimum of thirty (30) days divided and will expire SIX (6) MONTHS from the cause the application to become ABANDONE!	nety filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status	·				
1) Responsive to communication(s) filed on 22	<u>December 2003</u> .				
·— ·	is action is non-final.				
3) Since this application is in condition for allow					
Disposition of Claims					
4) Claim(s) 1,4-21,40 and 65 is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.  5) Claim(s) is/are allowed.  6) Claim(s) 1, 4-21, 40 and 65 is/are rejected.  7) Claim(s) is/are objected to.  8) Claim(s) are subject to restriction and/or election requirement.					
Application Papers					
9) The specification is objected to by the Examination The drawing(s) filed on is/are: a) and applicant may not request that any objection to the Replacement drawing sheet(s) including the correction of the sheet of the	ccepted or b) objected to by the formal or by the formal	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment(s)					
1) Notice of References Cited (PTO-892)	4)  Interview Summary Paper No(s)/Mail Da				
<ul> <li>2) Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date</li> </ul>	(T)	Patent Application (PTO-152)			

Application/Control Number: 09/171,740

Art Unit: 1615

#### **DETAILED ACTION**

Claims 1, 4-21, 40, 65 are pending.

#### Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 12/22/03 has been entered.

## Claim Rejections - 35 USC § 103

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
  - 1. Determining the scope and contents of the prior art.
  - 2. Ascertaining the differences between the prior art and the claims at issue.
  - 3. Resolving the level of ordinary skill in the pertinent art.
  - 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 4. Claims 1, 4-21, 40, 65 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shalaby et al. (WO 94/15587).

Application/Control Number: 09/171,740

Art Unit: 1615

Applicants claim a method of making microparticles of a sustained release ionic conjugate containing a free carboxyl group-containing biodegradeable polymer and a free amino group-containing drug which are ionically bonded to each other, the method comprising: obtaining a first solution in which said conjugate is dissolved, wherein the solution comprises at least one part acetone, acetonitrile, ethyl acetate, tetrahydrofuran, glyme or any combintion therof; adding said first solution through an atomizing nozzle to a first liquid to form a first dispersion, wherein said first liquid is miscible with said first solution, and said conjugate is not soluble in said first liquid and precipitates out of said first dispersion; and isolating said conjugate from said first dispersion.

Shalaby et al. disclose peptide-polymer ionic conjugate microparticles wherein the polymer is a polyester that is the same as the instant invention. See pages 4-5 and 6-7, Tables 1-3, 6 and Example 11. The disclosed peptide is either LHRH or somatostain. Example 11 of Shalaby teaches the instant methods. Ionic conjugates are formed by dissolving a biodegradable polymer in a liquid, while a peptide (drug) is dissolved in another liquid. These liquids are essentially mixed to form the peptide-polymer ionic conjugate and added to acetone. On pages 4-5 and 6-7, Stalaby discloses that tetrahydrofuran (THF) or acetonitrile, or mixtures thereof is substituted for or with acetone. The acetone/peptide-polymer solution is then injected into water or alcohol in small droplets. See page 27, lines 3-4. The polymer/peptide complex then separates immediately into small particles which are then subjected to reduced pressure to remove residual acetone and centrifuged. Shalaby is silent as to limitations of the instant claim 11, where the alcohol is maintained between 0 C to about -30 C or 0 C and -70 C. However, since the process of Shalaby is otherwise the same as the instant claims and results in the

Application/Control Number: 09/171,740

Art Unit: 1615

formation of microparticles, the temperature limitations of the instant claim 11 are not afforded patentable weight absent a demonstration of criticality thereto. Furthermore, it would be within the gambit of one skilled in the art to form the microparticles at a temperature that allowed for the quickest, most easily formed, or desirable microcapsules.

### Response to Arguments

5. Applicant's arguments filed 12/22/03 have been fully considered but they are not persuasive.

Applicants argue that the Shalaby reference does not teach that the first solution is added to the first liquid in the form of small droplets through an atomizing nozzle. It is the position of the examiner that Shalaby teaches injecting a first solution as small droplets to a first liquid to form a first dispersion. While the reference teaches uses a teflon filter, it is known in the art that syringes equipped with teflon filters are used for injection of solutions via 0.2  $\mu$  teflon filters. Such filters can be fitted with needles for better control of the injection and would produce small droplets. Both the instant application and the prior art desire control over adding the first solution as small droplets to a first liquid to form a first dispersion. Therefore, the rejection is maintained.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rachel M. Bennett whose telephone number is (571) 272-0589. The examiner can normally be reached on Monday through Friday, 8:00 A.M. to 4:30 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page can be reached on (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Page 5

Application/Control Number: 09/171,740

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

rmb

PRIMARY EXAMINER
GROUP 1500